Acute diphenyl diselenide treatment reduces hyperglycemia but does not change delta-aminolevulinate dehydratase activity in alloxan-induced diabetes in rats.
This study was designed to evaluate the effect of diphenyl diselenide in a classical model of alloxan-induced diabetes in rats. Oxidative stress is involved in alloxan toxic effects and we have hypothesized that diphenyl diselenide via its antioxidant properties could confer protection against alloxan pancreatic toxicity. Diabetes was induced by administration of alloxan (150 mg/kg, intravenously). Diphenyl diselenide (10 mg/kg, subcutaneously) was administered for 6 d before (prevention group) or for 6 d after (remediation group) diabetes induction. Diphenyl diselenide treatment reduced the blood glucose and fructosamine levels, which were increased in alloxan-treated rats. However, the delta-aminolevulinate dehydratase (delta-ALA-D) activity inhibited by alloxan was not restored by diphenyl diselenide. Moreover, diphenyl diselenide caused by itself an inhibition in hepatic and renal delta-ALA-D activity. Our findings suggest that the acute treatment with diphenyl diselenide reduces the hyperglycemia but does not improve delta-ALA-D activity decreased by alloxan. Although the dose of diphenyl diselenide used here for treating diabetic animals has been relatively high and produced toxic effects, the compound or analogous molecules might not be rejected as a promising anti-hyperglycemic agent.
Barbosa
Nilda Berenice de Vargas
NB
Centro de Ciências da Saúde, Fundação Universidade Federal do Pampa, Uruguaiana, CEP 97500-970, RS, Brasil. nvbarbosa@yahoo.com.br
Oliveira
Caroline
C
Araldi
Dioneia
D
Folmer
Vanderlei
V
Rocha
João Batista Teixeira
JB
Nogueira
Cristina Wayne
CW
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001555:Benzene Derivatives / Q000494:pharmacology* / Q000633:toxicity; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D019270:Fructosamine / Q000097:blood; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D016566:Organoselenium Compounds / Q000494:pharmacology* / Q000633:toxicity; D000623:Porphobilinogen Synthase / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
D001555:Benzene Derivatives; D001786:Blood Glucose; D016566:Organoselenium Compounds; C061132:diphenyldiselenide; D019270:Fructosamine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000623:Porphobilinogen Synthase